Catalog 01 Resources 02 How to order 03 CalculatorBlog Cart 03 Home 04
GH & Secretagogues

CJC-1295 without DAC Australia — Modified GRF(1-29)

CJC-1295 without DAC research peptide vial — TXLABS, ≥98% HPLC

From $99 AUD · ≥98% HPLC purity · third-party COA · ships Australia-wide

What is CJC-1295 without DAC?

CJC-1295 without DAC (Modified GRF 1-29, Mod GRF 1-29) is a short-acting GHRH analogue that stimulates pulsatile growth hormone secretion. This modified peptide is studied in laboratory research on the growth hormone-releasing hormone receptor and is frequently paired with a ghrelin mimetic in research protocols.

Specifications

What the research covers

CJC-1295 without DAC is more accurately described as modified GRF(1-29), and the more precise name is worth using because the product name invites confusion with a different molecule. It is a synthetic analogue of growth hormone-releasing hormone built on GHRH(1-29), the shortest N-terminal fragment that retains full agonist activity at the GHRH receptor, and carries four reported amino acid substitutions: D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27. Its molecular weight is near 3368 Da, roughly 10 Da above sermorelin's 3357.9 Da, the difference arising from those substitutions.

The D-alanine at position 2 does the essential work. Native GHRH and sermorelin are cleaved rapidly by dipeptidyl peptidase-4 at the N-terminal dipeptide, and replacing the L-alanine at position 2 with its D-isomer blocks that cleavage. The remaining substitutions are reported to address other degradation and oxidation liabilities, including the methionine at position 27 that sermorelin retains. Even so, this molecule carries no albumin-binding modification at all, and its reported circulating half-life remains short, on the order of minutes rather than hours. That is the entire point of the without DAC designation and the reason the two CJC-1295 forms are studied as separate research tools.

Published work using modified GRF(1-29) has examined GHRH receptor binding and Gs-coupled cAMP accumulation in pituitary cell preparations, the pulsatile pattern of growth hormone release that follows brief receptor engagement, and the combination of GHRH receptor agonism with ghrelin receptor agonism, since the two receptor systems are separate inputs converging on the same somatotroph population.

TXLABS supplies modified GRF(1-29) as an analytical reference material for laboratory research only. It is not an approved therapeutic good in Australia and is not supplied for human or veterinary administration.

Reading the certificate

The impurity population to expect at 29 residues is deletion and truncation sequences arising from incomplete coupling in solid-phase synthesis, and these can elute close to the parent, which is why mass-spectrometric identity carries more weight than a purity percentage. Confirm the observed mass against the expected value near 3368 Da, and specifically confirm it is not near 3647 Da, which would indicate DAC-bearing material, or near 3357.9 Da, which would indicate unsubstituted sermorelin. The D-alanine at position 2 introduces a stereochemical check as well: epimerisation produces a diastereomer of identical mass that only chromatography can resolve. TXLABS publishes third-party certificates for tested lots in the CoA library; no certificate is currently published for this compound. The lot certificate is available on request to support@txlabs.bio.

Storage and handling

At 29 residues this is a mid-length synthetic peptide, more fragile in solution than a pentapeptide and less so than a 44-mer. The lyophilised cake is stored at -20 °C, desiccated and protected from light, and brought to room temperature before the vial is opened so that condensation does not wet a hygroscopic powder. Reconstituted solution is held at 2-8 °C, shielded from light, and divided into single-use aliquots if any portion must be frozen, because each freeze-thaw cycle concentrates solute at the ice interface and drives aggregation of longer peptides preferentially. Add diluent gently down the vial wall and swirl rather than shake. Unlike its DAC-bearing counterpart, this molecule contains no reactive maleimide, so it is chemically simpler to store, and thiol-containing buffers pose no particular problem. Australian summer transit remains the practical risk: parcels in vehicles or letterboxes above 40 °C are best avoided by prompt collection and immediate refrigeration.

Working out concentration

The TXLABS vial is 10 mg. Reconstituted with 1 mL of bacteriostatic water it gives 10 mg/mL; with 2 mL, 5 mg/mL; with 5 mL, 2 mg/mL. At approximately 3368 Da, a 5 mg/mL solution corresponds to roughly 1.5 mM. This is close enough to the concentration figures for the DAC-bearing version that stock containers holding either should be labelled unambiguously if both are present, since the two solutions are visually identical and the molecules differ by about 280 Da. The reconstitution calculator resolves any vial and volume combination. These are worked concentration examples only and not a protocol.

How it relates to adjacent compounds

CJC-1295 with DAC is the same peptide carrying a maleimidopropionamide group that conjugates covalently to serum albumin, roughly 280 Da heavier and with a very different reported half-life. Sermorelin is the unmodified GHRH(1-29) parent, which shows what the four substitutions here were introduced to fix. Ipamorelin acts on the ghrelin receptor GHS-R1a rather than the GHRH receptor, which is why the two are studied as complementary inputs and are co-formulated in the combination vial. The GHRP hexapeptides stocked here, including GHRP-2, act at that same ghrelin receptor with different reported selectivity profiles again. Structural and receptor relationships only, with no implication about relative activity.

Frequently asked questions

Why is modified GRF(1-29) the better name for this compound? +
Because CJC-1295 without DAC describes the molecule by what it lacks, which invites confusion with the DAC-bearing compound that shares the name. Modified GRF(1-29) says what it is: the 29-residue N-terminal fragment of growth hormone-releasing hormone carrying four amino acid substitutions. Certificates and laboratory records are clearer when the descriptive name is used.
What do the four substitutions do? +
The D-alanine at position 2 blocks dipeptidyl peptidase-4 cleavage of the N-terminal dipeptide, which is the principal degradation route for native GHRH and the single most important change. The substitutions at positions 8, 15 and 27 are reported to address further degradation and oxidation liabilities, including replacing the methionine that sermorelin retains at position 27.
If it resists DPP-4, why is its half-life still short? +
Because DPP-4 cleavage is only one clearance route. The molecule has no albumin-binding modification of any kind, so it is cleared rapidly by other mechanisms including renal filtration, and its reported half-life stays in the range of minutes. Blocking one enzymatic pathway extends survival in plasma; it does not make a small peptide long-acting.
How does it differ from sermorelin analytically? +
By about 10 Da. Sermorelin is GHRH(1-29) with no substitutions at 3357.9 Da; modified GRF(1-29) carries four substitutions and sits near 3368 Da. That is a small enough gap that the resolution of the mass spectrometry method matters, and the chromatographic profile provides the supporting evidence. The two are distinct molecules, not grades of the same product.
Why is a D-amino acid a quality control issue? +
Because the D-alanine at position 2 can epimerise to the L-isomer during synthesis or storage, producing a diastereomer with exactly the same molecular mass as the target. Mass spectrometry cannot distinguish them. Reversed-phase HPLC can, which makes a single clean main peak more informative for this peptide than it would be for one built entirely from L-amino acids.
Is this compound scheduled in Australia? +
Scheduling status sits in the Poisons Standard and is revised by the TGA on a regular cycle, so it is date-dependent. CJC-1295 in either form is not registered on the ARTG, and the TGA has published guidance on unapproved peptide products that names CJC-1295. GHRH analogues also appear on the WADA Prohibited List, which is revised annually. Check tga.gov.au for the current position.
Can this material be treated as interchangeable with the DAC version? +
No. They are different molecules with a mass difference of roughly 280 Da and reported half-lives that differ by orders of magnitude, and no experiment comparing them would be valid if one were substituted for the other. The visual appearance of the powder and the reconstituted solution gives no clue, so the mass on the lot certificate is the only reliable discriminator.

Related compounds

Browse full catalog Reconstitution calculator